choriocarcinoma

The promising efficacy of its tumor treatment earns TRACON Pharmaceuticals Inc (NASDAQ: TCON) a Buy rating and $15 price target from BTIG. Tracon's lead compound, TRC105 (an anti-endoglin antibody) has generated promising efficacy in a variety of solid tumors, including HCC, RCC and angiosarcoma...